Re: CD20 may be a better target than CD19 anyway
2seventy Bio, the planned oncology spin-off of BLUE, will file an IND in the next few months for bbT369. This is an auto CAR-T that targets CD20 and CD79a, has split CD28 and 4-BB co-stim domains, and CBL-B knockout [1,2].
Also, a second IND will be for DARIC33. This is another auto CAR-T, but targets CD33, is under the control of rapamycin  and will be tested in both adult and paediatric patients. A next-gen version will target a second antigen and be enhanced (both undisclosed).
1 https://ashpublications.org/blood/article/132/Supplement 1/338/264550/Knockout-of-CBLB-Greatly-Enhances-Anti-Tumor